Camilla Sylvest - Novo Nordisk Head VP
| N1VO34 Stock | BRL 68.97 4.14 6.39% |
VP
Camilla Sylvest is Head VP of Novo Nordisk AS
| Age | 51 |
| Phone | 45 44 44 88 88 |
| Web | https://www.novonordisk.com |
Novo Nordisk Management Efficiency
The company has return on total asset (ROA) of 0.2169 % which means that it generated a profit of $0.2169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.72 %, meaning that it generated $0.72 on every $100 dollars invested by stockholders. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 4 records | VP Age | ||
| Brenda JD | Bio Techne | 65 | |
| Gerry Andros | Bio Techne | N/A | |
| Robert Gavin | Bio Techne | 55 | |
| Brenda Everson | Bio Techne | N/A | |
Management Performance
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 |
Novo Nordisk AS Leadership Team
Elected by the shareholders, the Novo Nordisk's board of directors comprises two types of representatives: Novo Nordisk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novo. The board's role is to monitor Novo Nordisk's management team and ensure that shareholders' interests are well served. Novo Nordisk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novo Nordisk's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Monique Carter, Head VP | ||
| Maziar Doustdar, Head VP | ||
| Lars Jorgensen, CEO Pres | ||
| Marcus Schindler, Head EVP | ||
| Karsten Knudsen, CFO VP | ||
| Henrik Wulff, Head VP | ||
| Ludovic Helfgott, Head VP | ||
| Camilla Sylvest, Head VP | ||
| Martin Lange, Head VP | ||
| Douglas Langa, Head VP |
Novo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novo Nordisk a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 1.59 T | |||
| Shares Outstanding | 2.25 B | |||
| Price To Book | 3.46 X | |||
| Price To Sales | 9.46 X | |||
| Revenue | 140.8 B | |||
| Gross Profit | 148.51 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Novo Stock
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.